Eagle Health Investments’s Lyell Immunopharma LYEL Stock Holding History

Eagle Health Investments’s Portfolio LYEL Stock Details LYEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,000	Closed	-$236K	–	30
2023 Q1	$236K	Hold	5,000	–	–	0.05%	27
2022 Q4	$347K	Hold	5,000	–	–	0.08%	26
2022 Q3	$733K	Hold	5,000	–	–	0.17%	26
2022 Q2	$652K	Hold	5,000	–	–	0.15%	26
2022 Q1	$505K	Hold	5,000	–	–	0.12%	28
2021 Q4	$774K	Hold	5,000	–	–	0.19%	27
2021 Q3	$1.48M	Hold	5,000	–	–	0.47%	26
2021 Q2	$1.62M	Buy	+5,000	New	+$1.64M	0.56%	27

Other funds holding LYEL

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OPL

Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Eagle Health Investments's LYEL Position: Q2 2023 in Review

Eagle Health Investments sold out of Lyell Immunopharma (LYEL) in Q2 2023, closing a stake of 5,000 shares — an estimated $236K sold.

Eagle Health Investments first reported a position in LYEL in Q2 2021 and held it in 8 quarters. The position peaked at $1.62M in Q2 2021. 99 funds tracked by Wall St. Rank hold LYEL as of Q2 2023.

Eagle Health Investments reported no remaining Lyell Immunopharma position as of Q2 2023 after selling out during the quarter.
Eagle Health Investments sold 5,000 Lyell Immunopharma shares in Q2 2023, an estimated $236K.
Eagle Health Investments first reported a position in Lyell Immunopharma in Q2 2021 and held it in 8 quarters.
Eagle Health Investments's Lyell Immunopharma position peaked at $1.62M in Q2 2021.
99 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2023.

Based on Eagle Health Investments's 13F filing for Q2 2023, filed 14 Aug 2023.